SOLICITATION NOTICE
B -- identify and select renal cancer cases in the Physicians’ Health Study (PHS) and the Women’s Health Study (WHS) cohorts for inclusion in an expanded genome-wide association study (GWAS) of renal cancer.
- Notice Date
- 6/1/2011
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NC110077-TG
- Archive Date
- 6/30/2011
- Point of Contact
- Terry Galloway, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
gallowaytl@mail.nih.gov, cr214i@nih.gov
(gallowaytl@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), plans to procure on a sole source basis services from Brigham and Women's Hospital, 900 Commonwealth Avenue East, 3rd Floor, Boston, MA 02215 to identify and select renal cancer cases in the Physicians' Health Study (PHS) and the Women's Health Study (WHS) cohorts for inclusion in an expanded genome-wide association study (GWAS) of renal cancer. This acquisition will be processed in accordance with simplified acquisition procedures in FAR Part 13.106 (b)(1). The North American Industry Classification System code is 541380 the business size standard is $12.0 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Performance shall be for twelve (12) months from date of award. The Division of Cancer Epidemiology and Genetics (DCEG) is an intramural research program of the National Cancer Institute (NCI), National Institutes of Health (NIH) that conducts population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. Separate genome-wide association study (GWAS) investigations conducted by investigators from the National Cancer Institute (NCI) and the International Agency for Research on Cancer (IARC) were recently combined to identify common genetic variants associated with renal cancer risk. DCEG investigators are seeking to expand the NCI GWAS in order to detect additional susceptibility loci across a wider range of allele frequencies and magnitudes of effect. In addition to identifying novel risk loci, the proposed GWAS will investigate genetic variants associated with renal cancer survival. The purpose of this procurement is to identify and select renal cancer cases in the Physicians' Health Study (PHS) and the Women's Health Study (WHS) cohorts, retrieve stored buffy coat and whole blood specimens for selected cases, and extract genomic DNA from these specimens for analysis in the expanded GWAS effort. Data on administrative and demographic characteristics (e.g., year of study enrollment, age at enrollment, sex) and established risk factors for renal cancer (e..g, smoking status, BMI, diagnosed hypertension) will be provided for selected cases. The Brigham and Women's Hospital (BWH) manages and stores the prospectively collected specimens from the PHS and the WHS. As the BWH is the only research institution that possesses the samples, they are the only institution that can process and ship the samples to the NCI for analysis in the GWAS of renal cancer. It is essential to have careful records and inventory of the specimens. Specimens collected prospectively in the PHS and WHS are used by a large number of investigators for research projects, including previous GWAS investigations conducted by the NCI. Since a large number of additional renal cancer cases and controls are needed to expand the NCI GWAS of renal cancer, it is critical to include specimens and data from the PHS and WHS in this effort. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisition on or before 11:00 AM EST on June 15, 2011 11:00 a.m. EST. No electronic capability statements will be accepted (i.e. email or fax) an original and one copy must be sent to the NCI Office of Acquisition to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Terry Galloway, Contract Specialist at gallowaytl@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-110077-TG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NC110077-TG/listing.html)
- Record
- SN02461611-W 20110603/110601234944-12a7b78f309a5235dc869c3d843f881a (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |